Should I buy or sell Myriad Genetics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MYGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYGN, but not buy additional shares or sell existing shares. View MYGN analyst ratings or view top-rated stocks .

What is Myriad Genetics' stock price target for 2024?

6 brokers have issued twelve-month price objectives for Myriad Genetics' shares. Their MYGN share price targets range from $14.00 to $31.00. On average, they expect the company's stock price to reach $23.17 in the next twelve months. This suggests a possible upside of 22.4% from the stock's current price. View analysts price targets for MYGN or view top-rated stocks among Wall Street analysts .

How have MYGN shares performed in 2024?

Myriad Genetics' stock was trading at $19.14 at the start of the year. Since then, MYGN stock has decreased by 1.1% and is now trading at $18.92. View the best growth stocks for 2024 here .

When is Myriad Genetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our MYGN earnings forecast .

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) released its quarterly earnings results on Tuesday, February, 27th. The company reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of $0.01 by $0.03. The firm had revenue of $196.60 million for the quarter, compared to the consensus estimate of $194.80 million. Myriad Genetics had a negative trailing twelve-month return on equity of 8.03% and a negative net margin of 34.96%. The firm's revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.20) EPS.

What ETFs hold Myriad Genetics' stock?

ETFs with the largest weight of Myriad Genetics (NASDAQ:MYGN) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM) , Invesco Biotechnology & Genome ETF (PBE) , Invesco S&P SmallCap Health Care ETF (PSCH) , WisdomTree BioRevolution Fund (WDNA) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) . SPDR S&P 600 Small Cap ETF (SLY) .

What guidance has Myriad Genetics issued on next quarter's earnings?

Myriad Genetics issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of 0.000-0.050 for the period, compared to the consensus estimate of -0.010. The company issued revenue guidance of $820.0 million-$840.0 million, compared to the consensus revenue estimate of $819.3 million.

What is Paul Diaz's approval rating as Myriad Genetics' CEO?

12 employees have rated Myriad Genetics Chief Executive Officer Paul Diaz on Glassdoor.com . Paul Diaz has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Myriad Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU) , Advanced Micro Devices (AMD) , NVIDIA (NVDA) , Gilead Sciences (GILD) , BioMarin Pharmaceutical (BMRN) , Incyte (INCY) , Puma Biotechnology (PBYI) , AT&T (T) , Alibaba Group (BABA) and Kratos Defense & Security Solutions (KTOS) .

How do I buy shares of Myriad Genetics?

Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Myriad Genetics have any subsidiaries?

The following companies are subsidiares of Myriad Genetics: Assurex Health Inc., Assurex Health Ltd, Counsyl, Crescendo Bioscience, Crescendo Bioscience LLC, Javelin Pharmaceuticals, Myriad Autoimmune, Myriad Genetic Laboratories Inc., Myriad Genetics Australia PTY LTD, Myriad Genetics B.V., Myriad Genetics Canada Corp, Myriad Genetics Espana SL, Myriad Genetics GK, Myriad Genetics GmbH, Myriad Genetics LTD, Myriad Genetics S.r.l., Myriad Genetics SAS, Myriad GmbH, Myriad International GmbH, Myriad Neuroscience, Myriad Services GmbH, Myriad Women’s Health, Myriad Women’s Health Inc, NaturNorth Technologies, Privatklinik Dr. Robert Schindlbeck, Rules-Based Medicine, and Sividon Diagnostics. Read More

NASDAQ:MYGN

Myriad Genetics (MYGN) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free MYGN Stock Alerts

$18.92

-0.25 (-1.30%)

(As of 04:33 PM ET)

Compare

Today's Range: $18.50
▼
$19.12
50-Day Range: $19.17
▼
$23.59
52-Week Range: $13.82
▼
$24.21

Volume: 476,896 shs
Average Volume: 629,677 shs
Market Capitalization: $1.70 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $23.17

Get Myriad Genetics alerts:

Myriad Genetics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 22.4% Upside
$23.17 Price Target
Short Interest: Bearish
6.31% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.60
Upright™ Environmental Score
News Sentiment: 0.35
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.36) to ($0.08) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.45 out of 5 stars

Medical Sector

498th out of 930 stocks

Diagnostic Substances Industry

6th out of 12 stocks

2.2

Analyst's Opinion

Consensus Rating
Myriad Genetics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 3 buy ratings, 2 hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Myriad Genetics has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.31% of the outstanding shares of Myriad Genetics have been sold short.
Short Interest Ratio / Days to Cover
Myriad Genetics has a short interest ratio ("days to cover") of 8.9.
Change versus previous month
Short interest in Myriad Genetics has recently increased by 18.12%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Myriad Genetics does not currently pay a dividend.
Dividend Growth
Myriad Genetics does not have a long track record of dividend growth.

4.1

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Myriad Genetics has received a 58.24% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Genomics analysis tools", "Computerized clinical decision support software", and "Medical technology engineering" products. See details.
Environmental Sustainability
The Environmental Impact score for Myriad Genetics is -0.60.

1.9

News and Social Media Coverage

News Sentiment
Myriad Genetics has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Myriad Genetics this week, compared to 4 articles on an average week.
Search Interest
Only 2 people have searched for MYGN on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Myriad Genetics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.00% of the stock of Myriad Genetics is held by insiders.
Percentage Held by Institutions
99.02% of the stock of Myriad Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Myriad Genetics are expected to grow in the coming year, from ($0.36) to ($0.08) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Myriad Genetics is -5.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Myriad Genetics is -5.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Myriad Genetics has a P/B Ratio of 1.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Myriad Genetics Stock (NASDAQ:MYGN)

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

MYGN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MYGN Stock News Headlines

April 16, 2024 | globenewswire.com

New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen

April 16, 2024 | americanbankingnews.com

Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Recommendation of "Hold" from Brokerages

April 16, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 15, 2024 | barrons.com

Myriad Genetics Inc.

April 11, 2024 | uk.investing.com

Myriad Genetics psychotropic test 'GeneSight' linked to lower hospitalization in depression patients

April 9, 2024 | globenewswire.com

Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing

April 6, 2024 | finance.yahoo.com

Novavax (NVAX) Down 3.2% Since Last Earnings Report: Can It Rebound?

March 21, 2024 | globenewswire.com

Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

April 16, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 21, 2024 | finanznachrichten.de

Myriad Genetics, Inc.: Myriad Genetics Announces Patent Granted for SneakPeek Snap Device

March 20, 2024 | globenewswire.com

Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device

March 16, 2024 | finance.yahoo.com

MYGN Apr 2024 30.000 call

March 16, 2024 | finance.yahoo.com

MYGN Aug 2024 21.000 call

March 16, 2024 | finance.yahoo.com

MYGN May 2024 18.000 call

March 14, 2024 | msn.com

Citi starts Catalyst at buy, cites rare disease drug portfolio

March 1, 2024 | markets.businessinsider.com

Myriad Genetics: Hold Rating Amidst Growth and Market Uncertainty

February 29, 2024 | finance.yahoo.com

Myriad Genetics Full Year 2023 Earnings: EPS Misses Expectations

February 28, 2024 | finance.yahoo.com

Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2023 Earnings Call Transcript

February 28, 2024 | finance.yahoo.com

Q4 2023 Myriad Genetics Inc Earnings Call

February 28, 2024 | markets.businessinsider.com

Myriad Genetics: Hold Rating Maintained Amid Balanced Performance and Cautious Outlook

February 27, 2024 | finance.yahoo.com

Myriad Genetics Inc (MYGN) Reports 11% Revenue Growth in Q4 and Full-Year 2023

February 27, 2024 | seekingalpha.com

Myriad Genetics, Inc. 2023 Q4 - Results - Earnings Call Presentation

February 27, 2024 | markets.businessinsider.com

Myriad Genetics Inc. Q4 Earnings Summary

February 27, 2024 | globenewswire.com

Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance

February 27, 2024 | globenewswire.com

Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

February 26, 2024 | msn.com

Myriad Genetics Q4 2023 Earnings Preview

February 22, 2024 | benzinga.com

Myriad Genetics Stock (NASDAQ:MYGN) Insider Trades

See More Headlines

Receive MYGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Diagnostic substances
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:MYGN
CUSIP: 62855J10
CIK: 899923
Web: www.myriad.com
Phone: (801) 584-3600
Fax: 801-584-3640
Employees: 2,700
Year Founded: 1991

Price Target and Rating

Average Stock Price Target: $23.17
High Stock Price Target: $31.00
Low Stock Price Target: $14.00
Potential Upside/Downside: +20.8%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-263,300,000.00
Net Margins: -34.96%
Pretax Margin: -34.81%
Return on Equity: -8.03%
Return on Assets: -5.24%

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 2.01
Quick Ratio: 1.87

Sales & Book Value

Annual Sales: $753.20 million
Price / Sales: 2.29
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.53 per share
Price / Book: 2.01

Miscellaneous

Outstanding Shares: 89,880,000
Free Float: 88,078,000
Market Cap: $1.72 billion
Optionable: Optionable
Beta: 1.95

Social Links

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Mr. Paul J. Diaz (Age 62)
CEO, President & Director
Comp: $1.88M
Dr. Kevin Richard Haas Ph.D. (Age 38)
Chief Technology Officer
Comp: $580.36k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MYGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Myriad Genetics stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MYGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYGN, but not buy additional shares or sell existing shares.
View MYGN analyst ratings or view top-rated stocks.
What is Myriad Genetics' stock price target for 2024?: 6 brokers have issued twelve-month price objectives for Myriad Genetics' shares. Their MYGN share price targets range from $14.00 to $31.00. On average, they expect the company's stock price to reach $23.17 in the next twelve months. This suggests a possible upside of 22.4% from the stock's current price.
View analysts price targets for MYGN or view top-rated stocks among Wall Street analysts.
How have MYGN shares performed in 2024?: Myriad Genetics' stock was trading at $19.14 at the start of the year. Since then, MYGN stock has decreased by 1.1% and is now trading at $18.92.
View the best growth stocks for 2024 here.
When is Myriad Genetics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our MYGN earnings forecast.
How were Myriad Genetics' earnings last quarter?: Myriad Genetics, Inc. (NASDAQ:MYGN) released its quarterly earnings results on Tuesday, February, 27th. The company reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of $0.01 by $0.03. The firm had revenue of $196.60 million for the quarter, compared to the consensus estimate of $194.80 million. Myriad Genetics had a negative trailing twelve-month return on equity of 8.03% and a negative net margin of 34.96%. The firm's revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.20) EPS.
What ETFs hold Myriad Genetics' stock?: ETFs with the largest weight of Myriad Genetics (NASDAQ:MYGN) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Invesco Biotechnology & Genome ETF (PBE), Invesco S&P SmallCap Health Care ETF (PSCH), WisdomTree BioRevolution Fund (WDNA) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).SPDR S&P 600 Small Cap ETF (SLY).

What guidance has Myriad Genetics issued on next quarter's earnings?: Myriad Genetics issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of 0.000-0.050 for the period, compared to the consensus estimate of -0.010. The company issued revenue guidance of $820.0 million-$840.0 million, compared to the consensus revenue estimate of $819.3 million.
What is Paul Diaz's approval rating as Myriad Genetics' CEO?: 12 employees have rated Myriad Genetics Chief Executive Officer Paul Diaz on Glassdoor.com. Paul Diaz has an approval rating of 74% among the company's employees.
What other stocks do shareholders of Myriad Genetics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AT&T (T), Alibaba Group (BABA) and Kratos Defense & Security Solutions (KTOS).
How do I buy shares of Myriad Genetics?: Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Myriad Genetics have any subsidiaries?: The following companies are subsidiares of Myriad Genetics: Assurex Health Inc., Assurex Health Ltd, Counsyl, Crescendo Bioscience, Crescendo Bioscience LLC, Javelin Pharmaceuticals, Myriad Autoimmune, Myriad Genetic Laboratories Inc., Myriad Genetics Australia PTY LTD, Myriad Genetics B.V., Myriad Genetics Canada Corp, Myriad Genetics Espana SL, Myriad Genetics GK, Myriad Genetics GmbH, Myriad Genetics LTD, Myriad Genetics S.r.l., Myriad Genetics SAS, Myriad GmbH, Myriad International GmbH, Myriad Neuroscience, Myriad Services GmbH, Myriad Women’s Health, Myriad Women’s Health Inc, NaturNorth Technologies, Privatklinik Dr. Robert Schindlbeck, Rules-Based Medicine, and Sividon Diagnostics.
Read More

This page (NASDAQ:MYGN) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Myriad Genetics (MYGN) Stock Price, News & Analysis

Myriad Genetics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Myriad Genetics Stock (NASDAQ:MYGN)

MYGN Stock Price History

MYGN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

MYGN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™